Key result
Long-term infusion of endothelin-1 increased mean arterial pressure by 16-19% and decreased renal blood flow and GFR similarly in control dogs and those with renin-angiotensin system blockade.
Why the study?
Does the renin-angiotensin system mediate the long-term cardiovascular and renal actions of endothelin in conscious dogs?
Does the renin-angiotensin system mediate the long-term cardiovascular and renal actions of endothelin in conscious dogs?
Long-term increases in circulating endothelin produce significant increases in arterial pressure and decreases in renal function that are not mediated by the renin-angiotensin system.
Answers are grounded in this paper and cite their sources.
ET-1 raises BP and impairs renal function independently of RAS in dogs; leaves open human relevance and therapeutic targeting.
Plasma endothelin levels are elevated approximately two- to threefold in a number of chronic pathophysiological conditions associated with hypertension. Results from recent studies indicate an important interaction between endothelin and the renin-angiotensin system (RAS). The role of the RAS in mediating the increases in arterial pressure produced by long-term pathophysiological elevations in circulating levels of endothelin is unknown. Therefore, the purpose of this study was to chronically increase circulating levels of endothelin within the pathophysiological range and determine the long-term cardiovascular and renal actions of endothelin in control dogs (n = 6) and in dogs pretreated with a converting-enzyme inhibitor (CEI) (n = 6) or CEI + angiotensin II (ANG II) replacement (n = 6). Infusion of endothelin-1 for 8 days at a rate of 2.5 ng.kg-1.min-1 increased plasma endothelin from 7.1 +/- 0.9 to 19.8 +/- 3.3 pg/ml. In control dogs, endothelin increased mean arterial pressure (MAP) by 19% (90 +/- 2 to 107 +/- 3 mmHg) while decreasing renal blood flow (RBF) by 30% and glomerular filtration rate (GFR) by 15-20%. Long-term elevation of circulating endothelin produced similar elevations in MAP in dogs pretreated with CEI (+16%) or CEI + ANG II (+17%). Similar decreases in RBF and GFR also occurred in response to endothelin in all three groups. These results indicate that although long-term increases in circulating endothelin within the pathophysiological range produce significant increases in arterial pressure, this effect does not appear to be mediated by the RAS.
No takes yet. Share an insight, caveat, or question.
Wilkins et al. (1995) studied this question. Endothelin-1 vs. Control dogs (no pretreatment) was evaluated on Mean arterial pressure (MAP). Long-term infusion of endothelin-1 increased mean arterial pressure by 16-19% and decreased renal blood flow and GFR similarly in control dogs and those with renin-angiotensin system blockade.
Synapse has enriched 10 related papers. Consider them for comparative context: